share_log

Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

Brookline Capital将Incternal Therapeutics升级为买入,宣布目标股价为2美元
Benzinga ·  2023/12/05 00:22

Brookline Capital analyst Kemp Dolliver upgrades Oncternal Therapeutics (NASDAQ:ONCT) from Hold to Buy and announces $2 price target.

布鲁克林资本分析师坎普·多利弗将Oncternal Therapeutics(纳斯达克股票代码:ONCT)从持有上调至买入,并宣布了2美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发